Proactive Investors - Run By Investors For Investors

UK regulator licenses two of Clinigen’s short-term jetlag treatments

With marketing authorisations secured, Clinigen’s jetlag drops and tablets can now be prescribed immediately by doctors
businessman with jetlag
The marketing authorisations are further examples of Clinigen’s unlicensed to licensed strategy

Two of Clinigen Group PLC’s (LON:CLIN) jetlag treatments have been granted marketing authorisations by the UK’s medicines regulator.

As the Medicines and Healthcare products Regulatory Agency has now licensed them, the Melatonin drops and tablets can now be prescribed right away. They can also be sold directly to wholesalers.

Previously, the treatments could only be prescribed when doctors had exhausted all other avenues.

READ: Clinigen takes back direct control of two of its oncology drugs in US

Given the likely sales boost from being licensed, Clinigen expects the treatments will be a “modest contributor of growth” within the commercial medicines business this year, offsetting a forecast decline in the unlicensed medicines division.

“This approval will ensure healthcare professionals can manage adult patients experiencing jet-lag with a licensed product, where before there was none,” said chief executive Shaun Chilton.

“Identifying and developing products to offer licensed options to prescribers and patients is an important part of our strategy in Commercial Medicines. We are continuing to explore and invest to further strengthen and diversify the portfolio.”

Havnig opened lower, Clinigen shares were up 1.2% to 1,021p on Wednesday afternoon, valuing the company at £1.3bn.

--Adds share price--

View full CLIN profile View Profile

Clinigen Group PLC Timeline

Related Articles

picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use